Big Pharma Talent Is Flocking to Biotech Startups. Nobody’s Saying ‘Are You Nuts?’

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

The Caveman’s Guide to Productivity
The Oxygen-Providing, High-Autonomy M&A Model: A Sign of Things to Come
After the Boom: How’s It Going for Big Pharma Vets At Startups?
How Gilead Can Play to Win in CAR-T Over the Next Decade